TickerTalks
Browse all tickers →
TickerTalks›$AORT
AOAORT

Artivion, Inc.

$AORT·$1.2B·Medical - Devices·Healthcare
$25.72+5.8%YTD-46.3%1Y-22.1%
Mentions · last 7 days
2026-07-09: 0 posts2026-07-10: 1 posts2026-07-11: 0 posts2026-07-12: 0 posts2026-07-13: 0 posts2026-07-14: 1 posts2026-07-15: 0 posts20%
Price updated 14m ago·X counts updated 21h ago
AOAORT
$AORTArtivion, Inc.
$25.72+5.80%2 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $AORT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventAcceleratingAI verdict · as of 2026-07-15

The move is getting stronger, with heavier trading behind it.

Artivion just closed Endospan + landed AMDS FDA approval — but the stock is -49% YTD, so the market hasn't rewarded the pipeline yet.

Artivion is a mid-cap aortic-medical-device franchise where the fundamental story has recently taken a step forward that the tape hasn't priced.

  • Revenue growth: Q1 2026 $116.3M (+17.5% YoY), Q4 2025 +19.2%, Q3 +18.4%, Q2 +15.3% — consistent mid-to-high-teens growth across the trailing year on BioGlue, heart preservation, and NEXUS aortic-arch products.
  • Fundamentals: Gross margin 62.9%, operating margin 7.8%, PE 82.7x (small trailing net income), PS 2.1x — expensive on PE but rich on gross-margin quality.
  • Twin catalysts landed in June:
  • Jun 29 / Jul 1: FDA approval of the AMDS (Ascyrus Medical Dissection Stent) Hybrid Prosthesis — an aortic-dissection therapy that Seeking Alpha framed as "supports accelerating growth and margin expansion."
  • May 18: Closed acquisition of Endospan Ltd. (Israeli medical-device company for innovative aortic treatments), coincident with FDA PMA approval of the NEXUS Aortic Arch System.
  • Q1 EPS miss overhang: $0.03 vs $0.06 estimate (-50%) on May 7 — the tape hasn't yet re-rated for the post-May approvals.
  • Insider tape: Jun 8 Andrew M. Green filed a Form 3 (new insider on-boarded); no recent discretionary S-Sales.
  • Setup: $23.13, -49% YTD, -27% over 12 months, sitting at only 14% of 52-week range and 37% below 200-day MA — the tape is priced as if the pipeline events didn't happen.

Aug 6 Q2 print is where AMDS and NEXUS commercial commentary should first appear; the analyst 2027 EPS jump to $0.41 (from 2026 $0.08) implies real earnings acceleration is expected — a print that supports that trajectory could catalyze a re-rating.

What to watch: Aug 6 Q2 print — AMDS launch commentary and any early commercial data, NEXUS + Endospan integration commentary; gross-margin trajectory (bull case is margin expansion on higher-priced devices); On-X Life Technologies segment progress; any procedural-volume commentary from aortic-dissection surgical community.

On the calendar: 2026-08-06 — Q2 2026 earnings (EPS est $0.13)

no sentimentrecent fda approvals

Read the AI verdict + X sentiment for $AORT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Manufactures and distributes surgical tissue implants and medical devices for cardiac and aortic surgery, including cryopreserved grafts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $AORT.

Medical - Devices · Healthcare

No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.

What this means for $AORT

Neutral — Manufactures and distributes surgical tissue implants and medical devices for cardiac and aortic surgery, including cryopreserved grafts; limited exposure means the surgical robotics procedure growth and AI-enabled device adoption is not a near-term catalyst or headwind.

Industry benchmark

12-name peer basket
-10.0%YTD
+5.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
82.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
3.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
7.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
2.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
62.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$0.03$0.06-50.0%
Q4 2025Feb 12, 2026$0.17$0.14+21.4%
Q3 2025Nov 6, 2025$0.16$0.14+14.3%
Q2 2025Aug 7, 2025$0.24$0.11+118.2%
Next earningsThu, Aug 6·consensus EPS $0.13

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$116.3M+17.5%61.5%6.4%$0.03$-6.8M
Q4 FY25$116.0M+19.2%60.1%6.2%$0.05$-7.9M
Q3 FY25$113.4M+18.4%65.6%11.1%$0.14$15.9M
Q2 FY25$113.0M+15.3%64.7%7.4%$0.03$11.7M

Forward consensus

5-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$486.2M$484.8M – $487.7M$0.08$0.08 – $0.096
FY27$539.8M$532.9M – $546.6M$0.41$0.40 – $0.426
FY28$600.8M$600.6M – $601.0M$0.79$0.70 – $0.964
FY29$677.9M$668.1M – $688.3M$1.19$1.17 – $1.213
FY30$763.9M$752.9M – $775.7M$1.57$1.54 – $1.603

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.18%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+3.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-33.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 46.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.255-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 11Andrew M GreenSVP, Regulatory and Quality44.0K sh$911KSellMar 4Jean F HollowaySVP, General Counsel9.0K sh$341KSellMar 3James P MackinCEO17.9K sh$676KSellMar 3Lance A BerryCFO6.3K sh$239KSellMar 3John E DavisChief Commercial Officer4.6K sh$173KSellMar 3Jean F HollowaySVP, General Counsel3.8K sh$145KSellMar 3Marshall S. StantonSVP, Clinical & MD Affair2.1K sh$81KSellMar 3Amy HortonVP, Chief Accounting Officer901 sh$34KSellMar 2James P MackinCEO14.9K sh$567KSellMar 2Amy HortonVP, Chief Accounting Officer641 sh$24K
1–10 of 26
+ 22 other (20 awards · 1 exempt · 1 other) in window

See when $AORT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJun 83
AI summary

Green Andrew M filed a Form 3 with the SEC, disclosing initial beneficial ownership of AORT securities. This filing is required under Section 16(a) of the Securities Exchange Act within 10 days of becoming a reporting person (officer, director, or 10%+ holder). The filing reports 4 shares of common stock. Form 3 filings establish a baseline ownership record for subsequent Form 4 (changes) and Form 5 (annual) filings, providing transparency into insider positions at AORT.

8-KPress release / Reg FDMay 188-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Artivion, Inc. (AORT) announced via Reg FD and Item 8.01 on May 18, 2026 the completion of its acquisition of Endospan Ltd., an Israeli medical device company specializing in innovative aortic treatment products including the Nexus™ endovascular system for aortic instability. A press release confirming the close was furnished as Exhibit 99.1. Financial terms are not disclosed in the available excerpt. This is a transformative acquisition for Artivion, adding Endospan's Nexus endovascular aortic technology to its cardiovascular portfolio and entering the high-growth minimally invasive aortic repair segment.

8-KShareholder voteMay 158-K — Item 5.07: Shareholder vote
AI summary

AORT held its Annual Meeting of stockholders around 2026-05-15 (8-K Item 5.07). Stockholders elected 9 directors to the board. A non-binding say-on-pay vote on executive compensation was conducted. Independent auditor ratification was approved. Routine governance event — monitor for unusually high withhold votes as an activist signal.

8-KMaterial agreementMay 78-K — Item 1.01: Material agreement · Item 2.02: Earnings release
AI summary

AORT reported period ending 2026-05-07 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

+ 10 other (3 13Gs · 2 proxys · 1 SD · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Devicezacks.com·15d agoArtivion: PMA Approval Supports Accelerating Growth And Margin Expansionseekingalpha.com·16d agoArtivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesisprnewswire.com·18d agoArtivion to Participate in the 2026 Truist Securities MedTech Conferenceprnewswire.com·36d agoEndospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch Systemgurufocus.com·59d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BSX$ISRG$ABT$BIO$BFLY$TMDX$ECOR$CLPT
Voices on X · last 7 days

No standout posts about $AORT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport